<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295047</url>
  </required_header>
  <id_info>
    <org_study_id>SPONCU101</org_study_id>
    <secondary_id>2005-000749-13</secondary_id>
    <nct_id>NCT01295047</nct_id>
  </id_info>
  <brief_title>Comparison of Medical Therapies in Marfan Syndrome.</brief_title>
  <official_title>Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiff University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are looking at the different impacts of atenolol, verapamil and perindopril
      on large artery and lv function in marfan syndrome. It is a double-blind, randomised
      cross-over trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators recruited 21 patients with confirmed diagnosis of Marfan syndrome from two
      centres. The investigators performed radial artery applanation tonometry and pulse wave
      analysis to derive central aortic pressure and haemodynamic indexes pre-and post
      administering Atenolol 75mg, Perindopril 4mg and Verapamil 240mgs each for four weeks with a
      two week wash-out between medications. All patients underwent detailed functional and
      anatomical echocardiographic assessments at each visit.

      Inclusion criteria were ages 16-60 years with no treatment or β-blocker or other monotherapy
      only for Marfan syndrome. Patients with previous aortic dissection or aortic surgery, severe
      valvular regurgitation, aortic diameter at the sinotubular junction ≥ 5.0cm,
      contraindications to specific drug treatment, e.g. asthma and β-blocker, or those who were
      pregnant or at risk of pregnancy were excluded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CENTRAL ARTERIAL PRESSURE</measure>
    <time_frame>18 weeks</time_frame>
    <description>CENTRAL ARTERIAL PRESSURE MEASURED BY APPLANATION TONOMETRY</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LARGE ARTERIAL STIFFNESS INDICES</measure>
    <time_frame>18 WEEKS</time_frame>
    <description>MEASURED BY ECHO AND BY PULSE WAVE VELOCITY/ANALYSIS BY APPLANATION TONOMETRY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Function</measure>
    <time_frame>18 WEEKS</time_frame>
    <description>GLOBAL AND REGIONAL MARKERS BY ECHO</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Marfan Syndrome</condition>
  <arm_group>
    <arm_group_label>ATENOLOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATENOLOL 75MG FOR 4 WEEKS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VERAPAMIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>240MG VERAPAML FOR 4 WEEKS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PERINDOPRIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4MG PERINDOPRIL FOR 4 WEEKS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <arm_group_label>ATENOLOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VERAPAMIL</intervention_name>
    <description>240 MG SR</description>
    <arm_group_label>VERAPAMIL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril</intervention_name>
    <description>4 MG</description>
    <arm_group_label>PERINDOPRIL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 16-60 years old with no treatment or β-blocker or other monotherapy only for
             Marfan syndrome

        Exclusion Criteria:

          -  Previous aortic dissection or aortic surgery

          -  Severe valvular regurgitation

          -  Aortic diameter at the sinotubular junction ≥ 5.0cm

          -  Contraindications to specific drug treatment, e.g. asthma and β-blocker

          -  Those who were pregnant or at risk of pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wales Heart Research Institute, Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>February 11, 2011</last_update_submitted>
  <last_update_submitted_qc>February 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>DR ALAN FRASER</name_title>
    <organization>WALES HEART RESEARCH INSTITUTE</organization>
  </responsible_party>
  <keyword>Marfan Syndrome</keyword>
  <keyword>Large arterial function</keyword>
  <keyword>LV function</keyword>
  <keyword>atenolol</keyword>
  <keyword>perindopril</keyword>
  <keyword>verapamil</keyword>
  <keyword>central arterial pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Marfan Syndrome</mesh_term>
    <mesh_term>Arachnodactyly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

